Regarding ICI therapy, patients with low SLC19A1 expression in ESCA, ureter and renal pelvis cancers, and urothelial cancers are more likely to achieve survival benefits, whereas those with high SLC19A1 expression in GBM and STAD are more likely to benefit from the treatment. The gene discussed is SLC19A1; the disease is gastric adenocarcinoma.